Research Paper Volume 12, Issue 1 pp 825—843

Association between SOD2 V16A variant and urological cancer risk

Figure 6. In silico analysis of SOD2 expression in prostate cancer patients (A), the investigation of disease-free survival (DFS) time (B) and overall survival (OS) time (C). Expression of SOD2 was down-regulated in prostate cancer tissues (Figure 6A, P < 0.05). Prostate cancer subjects with low SOD2 expression had a shorter DFS time than high SOD2 expression counterpart (Figure 6B, P = 0.047). No positive association was indicated for prostate cancer participants (Figure 6C, P = 0.630).